A case report of intractable nausea due to zoledronic acid-refractory hypercalcemia treated with denosumab
10.2512/jspm.10.552
- VernacularTitle:ゾレドロン酸抵抗性の高カルシウム血症による難治性悪心に対しデノスマブが奏功した1例
- Author:
Shingo Hagiwara
;
Takayuki Hisanaga
;
Takahiro Higashibata
;
Ritsuko Yabuki
;
Miho Shimokawa
;
Yasuo Shima
- Publication Type:Journal Article
- Keywords:
hypercalcemia;
zoledronic acid-refractory;
nausea;
denosumab
- From:Palliative Care Research
2015;10(4):552-556
- CountryJapan
- Language:Japanese
-
Abstract:
Introduction: We report a case of intractable nausea due to zoledronic acid-refractory hypercalcemia for which the nausea was alleviated with denosumab, thereby improving quality of life. Case: A 54-year-old woman presented with metastatic renal pelvis cancer. Elevation of serum calcium level and nausea were noted. After multiple antiemetics were administered with no appreciable symptomatic improvement, treatment with zoledronic acid resulted in a decrease in the calcium level and an improvement of nausea from Japanese version Support Team Assessment Schedule （STAS-J） 3 to 1. After the third dose of zoledronic acid, the corrected calcium level was 11.8 mg/dl, indicating refractory. Because no improvement in nausea was noted, treatment with denosumab was initiated. After the treatment, the calcium level decreased to 9.4 mg/dl, and nausea improved from STAS-J 4 to 0. The patient could spend good time with her family, albeit for a short time, and no progression of the symptoms or adverse events due to denosumab occurred until her death. Discussion: Denosumab appears to be useful for improvement of intractable nausea in zoledronic acid-refractory hypercalcemia.
